Medical-economic analysis of the treatment of advanced ovarian cancer
Dvorák, O.; Federmann, J.; Honzáková, L.
Ceskoslovenska Gynekologie 47(10): 755-763
1982
ISSN/ISBN: 0374-6852 PMID: 7159949 Document Number: 193995
Document emailed within 1 workday
Related Documents
Krommer, K. 1992: Treatment of patients with advanced ovarian cancer at the Gynecological Clinic of Pécs Medical University Orvosi Hetilap 133(19): 1151-1158Du Bois, A.; Lück, H.J.; Meier, W.; Möbus, V.; Costa, S.; Richter, B.; Warm, M.; Bauknecht, T.; Schröder, W.; Olbricht, S.; Nitz, U.; Jackisch, C. 1997: Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase IIi trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group Seminars in Oncology 24(5 Suppl 15: S15
Sun, X.; Li, X.; Li, H. 1995: Management of intestinal obstruction in advanced ovarian cancer an analysis of 57 cases Zhonghua Zhong Liu Za Zhi 17(1): 39-42
Rose, P.G.; Hunter, R.E. 1994: Advanced ovarian cancer in a woman with a family history of ovarian cancer, discovered at referral for prophylactic oophorectomy. A case report Journal of Reproductive Medicine 39(11): 908-910
Yazigi, R.; Wild, R.; Madrid, J.; Arraztoa, J. 1984: Ifosfamide treatment of advanced ovarian cancer Obstetrics and Gynecology 63(2): 163-166
Simm, S.; Wolna, M. 1973: Results of treatment of advanced stage of ovarian cancer Ginekologia Polska 44(1): 45-50
Hernádi, Z.; Juhász, B.; Póka, R.; Mahunka, I.; Lampé, L. 1987: Analysis of the effectiveness and adverse effects of the drug combinations CAP and CEP in the therapy of patients in the advanced stages of ovarian cancer Orvosi Hetilap 128(47): 2457-2461
Bruzzone, M.; Campora, E.; Merlini, L.; Giudici, S.; Bottero, G.; Iskra, L.; Donadio, M.; Ferrari, I.; Ragni, N. 1991: Ifosfamide and etoposide salvage treatment in advanced ovarian cancer Journal of ChemoTherapy 3(5): 332-334
Ozols, R.F. 2000: Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer Seminars in Oncology 27(3 Suppl 7: 3-7
Markman, M. 1995: Rationale for examining the combination of paclitaxel and ifosfamide in the treatment of advanced ovarian cancer Seminars in Oncology 22(3 Suppl 6: 88-89
Szepesi, T.; Szalay, S.; Breitenecker, G.; Schratter-Sehn, A.; Rogan, A.M.; Riss, T.; Wittich, G.; Heckenthaler, W.; Fasching, W.; Scheiber, V. 1983: Treatment of advanced ovarian cancer as an interdisciplinary task: surgery, histopathology, radiotherapy, and chemotherapy Wiener Klinische Wochenschrift 95(2): 37-49
Marin, A.C.; Rierson, B. 1979: Peripheral neuropathy secondary to cis-Dichlorodiammino-platinum (II) (Platinol). Treatment for advanced ovarian cancer Arizona Medicine 36(12): 898-899
Ehrlich, C.E.; Einhorn, L.; Stehman, F.B.; Blessing, J. 1983: Treatment of advanced epithelial ovarian cancer using cisplatin, adriamycin and cytoxan--the Indiana University experience Clinics in Obstetrics and Gynaecology 10(2): 325-335
Krizan, Z.; Cerný, V.; Manka, I.; Siracký, J.; Bohunický, L. 1977: Retrospective study about the treatment of advanced ovarian cancer with regard to chemotherapy carried out in the Oncological Institute of Slovakia Ceskoslovenska Gynekologie 42(2): 110-112
Ivanov, S.; Kovachev, E.; Kolev, N.; Bechev, B.; Kolev, N. 2016: Primary Cytoreductive Surgery versus Neoadjuvant Chemotherary in Treatment of Advanced Ovarian Cancer (Stage Iii C-Iv). our and Foreign Experience Akusherstvo i Ginekologiia 55 Suppl 1 Pt 1: 16-19
Evans, W.K.; Coyle, D.; Gafni, A.; Walker, H. 2003: Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis Chronic diseases in Canada 24(4): 102-107
Yen, M.L.; Chen, Y.C.; Lin, M.T.; Liu, M.C.; Tang, J.L.; Wang, C.H.; Hsieh, C.Y. 1992: High-dose chemotherapy with support by autologous bone marrow and GM-CSF in the treatment of advanced ovarian cancer: preliminary report of a new strategy Transplantation Proceedings 24(4): 1533-1535
Tanaka, K. 1989: Ovarian cancer--assessment of methods for cytogenetic analysis and chromosome aberrations found in ovarian cancer Rinsho Byori. Japanese Journal of Clinical Pathology Spec no 80: 268-280
Bertucci, F.; Viens, P.; Gravis, G.; Blaise, D.; Faucher, C.; Oziel-Taoeb, S.; Bardou, V.J.; Jacquemier, J.; Delpero, J.R.; Maraninchi, D. 1999: High-dose chemotherapy with hematopoietic stem cell support in patients with advanced epithelial ovarian cancer: analysis of 67 patients treated in a single institution Anticancer Research 19(2b): 1455-1461
Suwannarurk, K.; Thaweekul, Y.; Mairaing, K.; Poomtavorn, Y.; Tangtiang, K.; Piyawang, W.; Bhamarapravatana, K. 2015: Bevacizumab, Carboplatin and Paclitaxel Combination Treatment in Advanced Stage Ovarian Cancer: The First Experience in Thammasat University Hospital, Thailand: A Case Report Journal of the Medical Association of Thailand 98 Suppl. 3: S121-S125